Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Front Neurosci ; 11: 105, 2017.
Article in English | MEDLINE | ID: mdl-28326010

ABSTRACT

In healthy older adults, resveratrol supplementation has been shown to improve long-term glucose control, resting-state functional connectivity (RSFC) of the hippocampus, and memory function. Here, we aimed to investigate if these beneficial effects extend to individuals at high-risk for dementia, i.e., patients with mild cognitive impairment (MCI). In a randomized, double-blind interventional study, 40 well-characterized patients with MCI (21 females; 50-80 years) completed 26 weeks of resveratrol (200 mg/d; n = 18) or placebo (1,015 mg/d olive oil; n = 22) intake. Serum levels of glucose, glycated hemoglobin A1c and insulin were determined before and after intervention. Moreover, cerebral magnetic resonance imaging (MRI) (3T) (n = 14 vs. 16) was conducted to analyze hippocampus volume, microstructure and RSFC, and neuropsychological testing was conducted to assess learning and memory (primary endpoint) at both time points. In comparison to the control group, resveratrol supplementation resulted in lower glycated hemoglobin A1c concentration with a moderate effect size (ANOVARMp = 0.059, Cohen's d = 0.66), higher RSFC between right anterior hippocampus and right angular cortex (p < 0.001), and led to a moderate preservation of left anterior hippocampus volume (ANOVARMp = 0.061, Cohen's d = 0.68). No significant differences in memory performance emerged between groups. This proof-of-concept study indicates for the first-time that resveratrol intake may reduce glycated hemoglobin A1c, preserves hippocampus volume, and improves hippocampus RSFC in at-risk patients for dementia. Larger trials with longer intervention time should now determine if these benefits can be validated and extended to cognitive function.

2.
Am J Clin Nutr ; 103(4): 1045-54, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26912492

ABSTRACT

BACKGROUND: Low-normal concentrations of vitamin B-12 (VitB12) may be associated with worse cognition. However, previous evidence has been mixed, and the underlying mechanisms remain unclear. OBJECTIVE: We determined whether serum VitB12 concentrations within the normal range were linked to memory functions and related neuronal structures in patients with mild cognitive impairment (MCI). DESIGN: In a cross-sectional design, we assessed 100 amnestic MCI patients (52 women; age range: 50-80 y) with low- and high-normal VitB12 concentration (median split: 304 pmol/L) for memory functions with the use of the Auditory Verbal Learning Test. MRI was performed at 3 tesla (n= 86) for the estimation of the volume and microstructure of the hippocampus and its subfields as indicated by the mean diffusivity on diffusion-weighted images. With the use of a mediation analysis, we examined whether the relation between VitB12 and memory performance was partially explained by volume or microstructure. RESULTS: MCI patients with low-normal VitB12 showed a significantly poorer learning ability (P= 0.014) and recognition performance (P= 0.008) than did patients with high-normal VitB12. Also, the microstructure integrity of the hippocampus was lower in patients with low-normal VitB12, mainly in the cornu ammonis 4 and dentate gyrus region (P= 0.029), which partially mediated the effect of VitB12 on memory performance (32-48%). Adjustments for age, sex, education, apolipoprotein E e4 status, and total homocysteine, folate, and creatinine did not attenuate the effects. CONCLUSIONS: Low VitB12 concentrations within the normal range are associated with poorer memory performance, which is an effect that is partially mediated by the reduced microstructural integrity of the hippocampus. Future interventional trials are needed to assess whether supplementation of VitB12 may improve cognition in MCI patients even in the absence of clinically manifested VitB12 deficiency. This trial was registered at clinicaltrials.gov as NCT01219244.


Subject(s)
Cognitive Dysfunction/blood , Hippocampus/drug effects , Memory/drug effects , Vitamin B 12/blood , Aged , Aged, 80 and over , Apolipoprotein E4/blood , Cognition/drug effects , Cognitive Dysfunction/drug therapy , Creatinine/blood , Cross-Sectional Studies , Female , Folic Acid/blood , Genotyping Techniques , Hippocampus/metabolism , Homocysteine/blood , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Polymorphism, Single Nucleotide , Verbal Learning/drug effects , Vitamin B 12/administration & dosage
3.
Neuroimage ; 131: 226-38, 2016 05 01.
Article in English | MEDLINE | ID: mdl-26433119

ABSTRACT

Previous studies in older adults suggested beneficial effects of omega-3 fatty acid (FA) supplementation, aerobic exercise, or cognitive stimulation on brain structure and function. However, combined effects of these interventions in patients suffering from mild cognitive impairment (MCI) are unknown. Using a randomized interventional design, we evaluated the effect of combined omega-3 FA supplementation, aerobic exercise and cognitive stimulation (target intervention) versus omega-3 FA supplementation and non-aerobic exercise (control intervention) on cognitive function and gray matter volume in patients with MCI. Moreover, we analyzed potential vascular, metabolic or inflammatory mechanisms underlying these effects. Twenty-two MCI patients (8 females; 60-80years) successfully completed six months of omega-3 FA intake, aerobic cycling training and cognitive stimulation (n=13) or omega-3 FA intake and non-aerobic stretching and toning (n=9). Before and after the interventions, cognitive performance, magnetic resonance imaging of the brain at 3T (n=20), intima-media thickness of the internal carotid artery and serum markers of glucose control, lipid and B-vitamin metabolism, and inflammation were assessed. Intervention-related changes in gray matter volume of Alzheimer's disease (AD)-related brain regions, i.e., frontal, parietal, temporal and cingulate cortex were examined using voxel-based morphometry of high resolution T1-weighted images. After the intervention period, significant differences emerged in brain structure between groups: Gray matter volume decreased in the frontal, parietal and cingulate cortex of patients in the control intervention, while gray matter volume in these areas was preserved or even increased after the target intervention. Decreases in homocysteine levels in the target intervention group were associated with increases in gray matter volume in the middle frontal cortex (p=0.010). No significant differences in cognitive performance or other vascular, metabolic and inflammatory parameters were observed between groups. This pilot study provides preliminary evidence that omega-3 FA intake combined with aerobic exercise and cognitive stimulation prevents atrophy in AD-related brain regions in MCI patients, compared to omega-3 FA intake plus the control condition of stretching and toning. These promising findings should now be validated in a larger interventional trial.


Subject(s)
Cerebral Cortex/pathology , Cerebral Cortex/physiopathology , Cognitive Behavioral Therapy/methods , Cognitive Dysfunction/pathology , Cognitive Dysfunction/therapy , Exercise Therapy/methods , Fatty Acids, Omega-3/administration & dosage , Administration, Oral , Aged , Aged, 80 and over , Cerebral Cortex/drug effects , Cognitive Dysfunction/physiopathology , Combined Modality Therapy/methods , Diet Therapy/methods , Dietary Supplements , Female , Humans , Male , Middle Aged , Organ Size , Treatment Outcome
4.
Pain Med ; 14(11): 1786-96, 2013 Nov.
Article in English | MEDLINE | ID: mdl-23889888

ABSTRACT

OBJECTIVES: To describe postoperative pain within the first 24 hours after pediatric otolaryngologic surgery and to identify factors influencing postoperative pain. METHODS: One-hundred and thirty four children were included in a prospective cohort single center study. Outcome and process parameters were analyzed using the questionnaires of the German-wide project Quality Improvement in Postoperative Pain Management in Infants (QUIPSI). RESULTS: Maximal pain within the first 24 hours after typical otolaryngologic surgery reached average numeric rating scale values of 4.00 ± 3.49. About one fifth demanded more pain medications. Inpatient surgery, longer surgery, and major surgery were associated with more maximal pain. Analysis of analgesic use on the ward indicated insufficient utilization of these drugs, especially when piritramide was used (beta = 3.597, P = 0.039). When ibuprofen was used on the ward, this was significantly associated with the desire for more pain medication (odds ratio [OR]: 0.274, confidence interval [CI]: 0.103-0.725, P = 0.009). Children with American Society of Anesthesiologists status 2 were more fatigued after surgery than status 1 children (OR: 0.296, CI: 0.100-0.874, P = 0.028). Nausea was more common when ibuprofen was used on the ward for pain treatment (OR: 0.195, CI: 0.049-0.777, P = 0.020). CONCLUSIONS: QUIPSI is an easy tool to evaluate the quality of postoperative pain management following pediatric otolaryngologic surgery in children older than 3 years, especially in children older than 9 years. The maximal pain values within the first 24 hours are significant, so that pain therapy is required. It seems that both nonopioids and opioids are underdosed.


Subject(s)
Otorhinolaryngologic Surgical Procedures/adverse effects , Pain Management/methods , Pain Measurement/methods , Pain, Postoperative/diagnosis , Surveys and Questionnaires , Analgesics/therapeutic use , Child , Child, Preschool , Female , Humans , Male , Pain, Postoperative/drug therapy , Prospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...